Abstract:The chemokine receptor CXCR4 is required for the entry of human immunodeficiency virus type 1 (HIV-1) into target cells and its expression correlates with more profound pathogenicity, rapid progression to acquired immunodeficiency syndrome (AIDS), and greater AIDS-related mortality. There is still no cure for AIDS and no method for preventing or eradicating HIV-1 infection. HIV-1 entry begins with the interaction of the viral envelope glycoprotein gp120 and the primary receptor CD4, and subsequently with the coreceptors, CCR5 or CXCR4, on the host cells. Blocking the interaction of HIV-1 and its coreceptors is therefore a promising strategy for developing new HIV-1 entry inhibitors. This approach has a dual benefit, as it prevents HIV-1 infection and progression while also targeting the reservoirs of HIV-1 infected, coreceptor positive macrophages and memory T cells. To date, multiple classes of CXCR4-targeted anti-HIV-1 inhibitors have been discovered and are now at different preclinical and clinical stages. In this review, we highlight the studies of CXCR4-targeted small-molecule and peptide HIV-1 entry inhibitors discovered during the last two decades and provide a reference for further potential HIV-1 exploration in the future. Impact statement This minireview summarized the current progress in the identification of CXCR4-targeted HIV-1-entry inhibitors based on discovery/developmental approaches. It also provided a discussion of the inhibitor structural features, antiviral activities, and pharmacological properties. Unlike other reviews on anti-HIV-1 drug development, which have generally emphasized inhibitors that target intracellular viral replication and host genomic integration, this review focused on the drug discovery approaches taken to develop viral-entry inhibitors aimed at disturbing the initial step of viral interaction with uninfected host cells and preventing the subsequent viral replication/genomic integration. This review amalgamated recently published and important work on bivalent CXCR4-targeted anti-HIV-1-entry candidates/conjugates, discussed the research challenges faced in developing drugs to prevent and eradicate HIV-1 infection, and provided a perspective on strategies that can lead to future drug discoveries. The findings and strategies summarized in this review will be of interest to investigators throughout the microbiological, pharmaceutical, and translational research communities.

Medicinal chemistry of small molecule CCR5 antagonists for blocking HIV-1 entry: a review of structural evolution.

Recent Progress in Small Molecule CCR5 Antagonists As Potential HIV-1 Entry Inhibitors

Small Molecular CCR5 Antagonists As HIV Inhibitors:A Review of Recent Research

Advances of CCR5 antagonists: From small molecules to macromolecules

Progress in the Research of Small Molecule CCR5 Antagonists

The Research of Anti-HIV Drugs Small Molecular CCR5 Antagonist

Discovery of Non-Peptide Small Molecular Cxcr4 Antagonists As Anti-Hiv Agents: Recent Advances and Future Opportunities

Research and Development of CCR5-targeted Small Molecule Anti-AIDS Drugs

Recent advances in the development of small-molecule CCR5 inhibitors for HIV.

Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives As a Novel Series of CC-Chemokine Receptor 5 Antagonists.

Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly

Design, Synthesis, and Biological Activity of Novel Octahydro-1H-pyrrolo[3,2-c]pyridine Derivatives As C-C Chemokine Receptor Type 5 (CCR5) Antagonists

Advances in the Research of Chemokine Receptors Antagonists As Anti-Hiv Agents

Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy

Chemokine Receptor CCR5 Antagonist Maraviroc: Medicinal Chemistry and Clinical Applications.

Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex

Discoveries and developments of CXCR4-targeted HIV-1 entry inhibitors

The Chemical Diversity and Structure-Based Evolution of Non-Peptide CXCR4 Antagonists with Diverse Therapeutic Potential.

Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.

Identification of Potential CCR5 Inhibitors Through Pharmacophore-Based Virtual Screening, Molecular Dynamics Simulation and Binding Free Energy Analysis

CCR5 Antagonist TD-0680 Uses a Novel Mechanism for Enhanced Potency Against HIV-1 Entry, Cell-mediated Infection, and a Resistant Variant